| Virak Tan, MD | |
|
90 Bergen St, Doc 1200, Newark, NJ 07103-2425 | |
| (973) 972-2150 | |
| (973) 972-2155 |
| Full Name | Virak Tan |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 30 Years |
| Location | 90 Bergen St, Newark, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841373438 | NPI | - | NPPES |
| 8555907 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | 25MA07231500 (New Jersey) | Primary |
| Entity Name | Institute For Hand And Arm Surgery Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972989499 PECOS PAC ID: 0547578411 Enrollment ID: O20150928000940 |
News Archive
A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in St. Louis.
Educating people with diabetes in a primary-care setting with sustained, comprehensive intervention resulted in significant improvement in disease management and overall health, according to a study published in the current issue of Diabetes Care, a journal of the American Diabetes Association (ADA).
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson's disease (PD) patients with motor fluctuations. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management.
Engineers have for the first time created a simulator mimicking the mechanical behavior of the human torso - which could lead to innovations in the design of medical back supports.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Virak Tan, MD 30 Bergen St, Admc 12 1205, Newark, NJ 07107-3000 Ph: () - | Virak Tan, MD 90 Bergen St, Doc 1200, Newark, NJ 07103-2425 Ph: (973) 972-2150 |
News Archive
A change in the formula of the frequently abused prescription painkiller OxyContin has many abusers switching to a drug that is potentially more dangerous, according to researchers at Washington University School of Medicine in St. Louis.
Educating people with diabetes in a primary-care setting with sustained, comprehensive intervention resulted in significant improvement in disease management and overall health, according to a study published in the current issue of Diabetes Care, a journal of the American Diabetes Association (ADA).
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced that it has completed enrollment of its ADVANCE-PD trial. ADVANCE-PD is a multinational Phase III trial of its late-stage product IPX066 in advanced Parkinson's disease (PD) patients with motor fluctuations. IPX066 is an investigational extended release carbidopa-levodopa product intended to rapidly achieve and sustain effective blood concentrations of levodopa, potentially improving PD clinical symptom management.
Engineers have for the first time created a simulator mimicking the mechanical behavior of the human torso - which could lead to innovations in the design of medical back supports.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
› Verified 6 days ago
Dr. Vishnu Choudhary Potini, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 90 Bergen St, Doc Suite 7300, Newark, NJ 07103 Phone: 973-972-2150 | |
Dr. Sujoy Menon, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Lyons Ave, Newark, NJ 07112 Phone: 732-447-8095 | |
Dr. Jose Francisco Colon, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 638 Mount Prospect Ave, Newark, NJ 07104 Phone: 973-481-4040 Fax: 973-481-1338 | |
Mark C Reilly, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 90 Bergen St, Doc 1200, Newark, NJ 07103 Phone: 973-972-2150 Fax: 973-972-2155 | |
Dr. Michael Mark Vosbikian, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 205 S Orange Ave, Newark, NJ 07103 Phone: 973-972-0763 Fax: 973-972-3897 | |
Dr. Garret Lee Sobol, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 90 Bergen Street, 7th Fl., Ste. 7300, Newark, NJ 07101 Phone: 973-972-5350 | |
Sanjeev Sabharwal, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 90 Bergen St, Doc 1200, Newark, NJ 07103 Phone: 973-972-2150 Fax: 973-972-2155 |